NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple May Conferences

Caladrius Biosciences, Inc. - $CLBS |

NeoStem, Inc. ($NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in May.

Regenerative Medicine Foundation 2014 Conference

  • Venue: The Claremont Hotel, 41 Tunnel Road, Berkeley, CA
  • Website: www.regmedcon.org

Session 1:

  • Date and Time: Monday, May 5, 2014, 4:15 PM PST
  • Panelist: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Leveraging Standards to Expedite Clinical Product Delivery and Biobanking Services

Session 2:

  • Date and Time: Tuesday, May 6, 2014, 2:15 PM PST
  • Panelist: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Product Development Towards Commercialization in Regenerative Medicine

Terrapinn's 9th Annual World Stem Cells & Regenerative Medicine Congress 2014

Session 1:

  • Date and Time: Tuesday, May 20, 2014, 5:15 PM BST
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Case Study: AMR-001 for post AMI: enhancing the body's healing response

Session 2:

  • Date and Time: Wednesday, May 21, 2014, 2:30 PM BST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Understanding the path to bring your cell therapy to market

Session 3:

  • Date and Time: Thursday, May 22, 2014, 9:35 AM BST
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Understanding market place acceptance and market positioning of your cell therapy

Third Annual Marcum Microcap Conference

  • Date and Time: Thursday, May 29, 2014, 11:30 AM EST
  • Venue: Grand Hyatt New York, 109 East 42nd Street, New York, NY
  • Speaker: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: Company Presentation
  • Website: www.marcumllp.com/microcap

BioKorea 2014 International Convention

  • Venue: Kintex -- Goyang City, Gyeonggi-do, South Korea
  • Website: www.biokorea.org

Session 1 - Overview of Stem Cell and Regenerative Medicine Industry:

  • Date and Time: Thursday, May 29, 2014 10:00 AM KST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Title: State of the RM Industry in the US and Global

Session 2 - Rapid Snapshots of Stem Cell and Regenerative Medicine Companies:

  • Date and Time: Thursday, May 29, 2014 4:30 PM KST
  • Speaker: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Title: Alliance's Technology and Research Achievements

11th International Symposium on Stem Cell Therapy

  • Venue: University Hospital Gregorio Maranyon - Madrid, Spain
  • Website: cardiovascularcelltherapy.com

Session 1:

  • Date and Time: Thursday, May 29, 2014, 5:20 PM CEST
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Exosomes and cardiac repair after myocardial infarction

Session 2:

  • Date and Time: Thursday, May 29, 2014, 6:30 PM CEST
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Clinical research in stem cell therapy: Advances, barriers and pitfalls

Session 3:

  • Date and Time: Friday, May 30, 2014, 11:30 AM CEST
  • Panel Chair: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Late Breaking Clinical Trials

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's ability to consummate the CSC acquisition and the Company's ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's CD34 Cell Program and T Regulatory Cell Program and other cell therapies (including Melapuldencel-T if CSC is successfully acquired), the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
CANIF Canoel Intl Energy Ltd 0.03 0.00 0.00 0

Comments

Private Markets

Snapchat

Snapchat is the fastest way to share a moment with friends. The mobile app, allows users to not only share photos with friends but also control how long they can…

MyForce, Inc.

As parents, we constantly worry about the safety of our loved ones. The media bombards us with incidents from across the nation school shootings, frequent assaults on campuses, and crimes…